Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Arecor Therapeutics PLC ( (GB:AREC) ) just unveiled an announcement.
Arecor Therapeutics plc announced the grant of 230,000 options to its Chief Financial Officer, David Ellam, under the company’s Long Term Incentive Plan and All Employee Share Ownership Plan. This move is part of Arecor’s strategy to incentivize and retain key management personnel, potentially impacting the company’s operational focus and aligning management interests with shareholder value.
More about Arecor Therapeutics PLC
Arecor Therapeutics plc is a globally focused biopharmaceutical company that enhances existing therapeutic products to transform patient care. Utilizing its proprietary Arestat™ technology platform, Arecor develops a portfolio of proprietary products in diabetes and other indications, collaborating with leading pharmaceutical and biotechnology companies.
YTD Price Performance: -48.30%
Average Trading Volume: 17,913
Technical Sentiment Signal: Buy
Current Market Cap: £14.35M
For a thorough assessment of AREC stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue